Oxeia Biopharma in the News
News Release: KANSAS CITY AREA RESIDENTS ASKED TO PARTICIPATE IN PHASE 2 TRIAL OF OXE103
BOSTON, MA (December 21, 2021) – Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury is actively recruiting participants for its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center. OXE103 could advance treatment directly addressing the underlying pathology of concussion (mTBI). The program seeks qualified volunteers from the Kansas City area to participate in this study, which could help people with continued symptoms after sustaining a concussion.
The Defense Post: Veterans Have More to Fear from Mild Traumatic Brain Injuries than Expected
Writing in support of the TBI and PTSD Law Enforcement Training Act, Dr. Michael Wyand, CEO of Oxeia Biopharmaceuticals, calls for adding funding to the bill for finding an effective treatment for concussion.
Public Service Announcement: Phase 2 clinical trial for Oxeia’s concussion drug, OXE103
The Center for Concussion Management at the University of Kansas Health System, in partnership with the University of Kansas Medical Center, is looking for volunteers for a new concussion treatment research study.
Oxeia CEO Michael Wyand participated in OneNucleus BioWednesday Webinar: Prevention vs. Cure
If you can’t remove all risk can you at least treat the outcome? This session included a discussion of Oxeia’s concussion drug, OXE103, which is in Phase 2 clinical trials. Click “Read More” to watch the video.
One Nucleus: Dr. Michael Wyand to participate in panel
Oxeia Biopharmaceuticals CEO, Dr. Michael Wyand, is participating in One Nucleus BioWednesday Webinar on concussions on Wednesday, July 14, 2021 from 11:00 am to noon Eastern Daylight Time: Prevention vs. Cure – If you can’t remove all risk can you at least treat the outcome? Panelists will discuss current R&D for concussion treatment, new technologies for diagnosing and monitoring concussions and the case for investing in new drugs to treat concussions.
Roll Call: Concussions and First Responders
Writing in support of the TBI and PTSD Law Enforcement Training Act, Dr. Michael Wyand, CEO of Oxeia Biopharmaceuticals, calls for adding funding to the bill for finding an effective treatment for concussion.
The Sports Column: COVID Didn’t Bench NFL Football, But Head Injuries/ Concussions Could
Oxeia’s Co-founder and Chief Scientific Officer and Director of Trauma Surgery at Scripps Mercy Hospital and free agent defensive back, Richard Sherman say i it’s time for football to approach brain injury with the same zeal it has addressed COVID-19.
Drug Discovery News: One Nucleus announces life science award shortlist
Oxeia named a One Nucleus finalist for annual BioNewsRound Award for the company’s announcement of the initiation of Phase 2 trial for its drug treatment for concussion, OXE103. The award, which recognizes life science companies with exciting developments, will be announced at the annual Genesis conference on December 10, 2020.
The Brain Health Magazine: It’s Time to Find a Cure for Concussions
Dr. Michael Wyand, CEO of Oxeia Biopharmaceuticals and Dr. Chris Nowinski, cofounder and CEO of the Concussion Legacy Foundation, explain why we need to devote more resources to advancing drug research and development for treatment of concussions.
GEN: Spotting Brain Injury in the Bloodstream
Oxeia CEO Michael Wyand is interviewed by Lindsay Gray of Genetic Engineering and Biotechnology News (GEN) on the company’s Phase 2 clinical trial of OXE103 for treating concussions.
News Release: Oxeia announces initiation of Phase 2 trial for OXE103
SAN DIEGO,CA (Oct. 21, 2020) – Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, announced today initiation of a Phase 2 clinical trial of OXE103 for treating concussion.
Concussion Alliance Interview
Concussion Alliance Interviews the CEO of Oxeia, Michael Wyand and co-founder and chief scientific officer, Dr. Vishal Bansal on the company’s work developing a drug treatment for concussion.
Talking Concussions with Brain Injury Radio Host Kim Justus
Oxeia's Chief Scientific Officer Vishal Bansal shared his knowledge of the science behind concussions, as well as his hopes for future treatments on "Recovery Now," on the Brain Injury Network. Dr. Bansal told the host, Kim Justus, that the drug Oxeia is developing for treating concussions is targeting the 20% of concussion sufferers who don't recover in 28 days from their injury.
The Hill: Mild Traumatic Brain Injuries Can Lead to a Lifetime of Health Issues for Soldiers
Concussions are a serious health problem in the military. In January, 2020, 109 US servicemen in Iraq suffered traumatic brain injury from Iranian airstrikes. But this is just the latest occurrence; in the last 9 years over 413,000 troops were diagnosed with TBI.
In this article, Oxeia co-founder and chief scientific officer, Vishal Bansal, calls on Congress, the Pentagon, and the medical establishment to increase their commitment to finding an effective treatment to protect our proud members of the military.
News Release: Oxeia preparing for Phase 2 human clinical studies
Oxeia Biopharmaceuticals' CEO Michael Wyand, DVM, PhD, will participate in a panel discussion on redefining therapeutics areas and new technology paradigms at the Genesis 2019 Life Sciences Conference in London in December. Oxeia is preparing for the launch of Phase 2 human clinical studies for its therapeutic drug to treat concussions.
CNBC: Betting on software and against concussions
49ers star Richard Sherman is betting on software and against concussions as he dives into start-ups. One of the startups is Oxeia Biopharmaceuticals, which is developing a concussion drug that would treat the immediate symptoms and the underlying damage.
CBS Sports Radio: Richard Sherman stops by the Tiki and Tierney Show
San Francisco 49ers cornerback and Oxeia board member Richard Sherman stops by the Tiki and Tierney Show to talk about concussions and Oxeia's research.
News Release: Dr. Michael Wyand appointed as CEO
Oxeia Biopharmaceuticals Inc. announces the appointment of Michael Wyand, DVM, PhD as Chief Executive Officer. Dr. Wyand will also join Oxeia’s Board of Directors.
FiercePharma: Richard Sherman Joins Oxeia Advisory Board
NFL All-Pro Richard Sherman joins Oxeia board as it readies phase 2 concussion drug research
Richard Sherman, NFL All-Pro, Joins Advisory Board
Oxeia Biopharmaceuticals Inc. announces Richard Sherman, cornerback of the Seattle Seahawk’s (National Football League), as a member of its Advisory Board.
“I became an advisor to Oxeia to contribute to an action that could change the face of how concussions are treated. Wouldn’t it be great if football players, hockey players and boxers, among others, could play their sport without the constant worry of repercussions from getting walloped in the head? Oxeia’s progress toward the delivery of a treatment for concussions fills me with great excitement about the future of sports.”
Richard Sherman
Cornerback for the San Francisco 49ers and
Advisory Board Member, Oxeia Biopharmaceuticals